170 related articles for article (PubMed ID: 25213463)
1. The inoculum effect of antibiotics against CTX-M-extended-spectrum β-lactamase-producing Escherichia coli.
Wu N; Chen BY; Tian SF; Chu YZ
Ann Clin Microbiol Antimicrob; 2014 Sep; 13():45. PubMed ID: 25213463
[TBL] [Abstract][Full Text] [Related]
2. Extended-spectrum cephalosporins and the inoculum effect in tests with CTX-M-type extended-spectrum β-lactamase-producing Escherichia coli: potential clinical implications of the revised CLSI interpretive criteria.
Kang CI; Cha MK; Kim SH; Wi YM; Chung DR; Peck KR; Lee NY; Song JH
Int J Antimicrob Agents; 2014 May; 43(5):456-9. PubMed ID: 24690213
[TBL] [Abstract][Full Text] [Related]
3. Effects of inoculum and beta-lactamase activity in AmpC- and extended-spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae clinical isolates tested by using NCCLS ESBL methodology.
Queenan AM; Foleno B; Gownley C; Wira E; Bush K
J Clin Microbiol; 2004 Jan; 42(1):269-75. PubMed ID: 14715764
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of beta-lactam antibiotics against CTX-M-producing Escherichia coli.
Tärnberg M; Ostholm-Balkhed A; Monstein HJ; Hällgren A; Hanberger H; Nilsson LE
Eur J Clin Microbiol Infect Dis; 2011 Aug; 30(8):981-7. PubMed ID: 21298459
[TBL] [Abstract][Full Text] [Related]
5. Cefepime and the inoculum effect in tests with Klebsiella pneumoniae producing plasmid-mediated AmpC-type beta-lactamase.
Kang CI; Pai H; Kim SH; Kim HB; Kim EC; Oh MD; Choe KW
J Antimicrob Chemother; 2004 Dec; 54(6):1130-3. PubMed ID: 15486080
[TBL] [Abstract][Full Text] [Related]
6. Cefepime, piperacillin-tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae.
Thomson KS; Moland ES
Antimicrob Agents Chemother; 2001 Dec; 45(12):3548-54. PubMed ID: 11709338
[TBL] [Abstract][Full Text] [Related]
7. Comparative assessment of inoculum effects on the antimicrobial activity of amoxycillin-clavulanate and piperacillin-tazobactam with extended-spectrum beta-lactamase-producing and extended-spectrum beta-lactamase-non-producing Escherichia coli isolates.
López-Cerero L; Picón E; Morillo C; Hernández JR; Docobo F; Pachón J; Rodríguez-Baño J; Pascual A
Clin Microbiol Infect; 2010 Feb; 16(2):132-6. PubMed ID: 19614715
[TBL] [Abstract][Full Text] [Related]
8. Effect of inoculum size on the antibacterial activity of cefpirome and cefepime against Klebsiella pneumoniae strains producing SHV extended-spectrum beta-lactamases.
Bedenić B; Beader N; Zagar Z
Clin Microbiol Infect; 2001 Nov; 7(11):626-35. PubMed ID: 11737087
[TBL] [Abstract][Full Text] [Related]
9. The Inoculum Effect in the Era of Multidrug Resistance: Minor Differences in Inoculum Have Dramatic Effect on MIC Determination.
Smith KP; Kirby JE
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784837
[TBL] [Abstract][Full Text] [Related]
10. In vitro killing of parenteral beta-lactams against standard and high inocula of extended-spectrum beta-lactamase and non-ESBL producing Klebsiella pneumoniae.
Burgess DS; Hall RG
Diagn Microbiol Infect Dis; 2004 May; 49(1):41-6. PubMed ID: 15135499
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
Jang W; Park YJ; Park KG; Yu J
J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
[TBL] [Abstract][Full Text] [Related]
12. [Investigation of beta-lactamase genes and clonal relationship among the extended-spectrum beta-lactamase producing nosocomial Escherichia coli isolates].
Görgeç S; Kuzucu Ç; Otlu B; Yetkin F; Ersoy Y
Mikrobiyol Bul; 2015 Jan; 49(1):15-25. PubMed ID: 25706727
[TBL] [Abstract][Full Text] [Related]
13. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
[TBL] [Abstract][Full Text] [Related]
15. Detection of Escherichia coli and associated β-lactamases genes from diabetic foot ulcers by multiplex PCR and molecular modeling and docking of SHV-1, TEM-1, and OXA-1 β-lactamases with clindamycin and piperacillin-tazobactam.
Shahi SK; Singh VK; Kumar A
PLoS One; 2013; 8(7):e68234. PubMed ID: 23861873
[TBL] [Abstract][Full Text] [Related]
16. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula.
Maglio D; Ong C; Banevicius MA; Geng Q; Nightingale CH; Nicolau DP
Antimicrob Agents Chemother; 2004 Jun; 48(6):1941-7. PubMed ID: 15155182
[TBL] [Abstract][Full Text] [Related]
17. Activity in vitro of twelve antibiotics against clinical isolates of extended-spectrum beta-lactamase producing Escherichia coli.
Sorlózano A; Gutiérrez J; Romero JM; de Dios Luna J; Damas M; Piédrola G
J Basic Microbiol; 2007 Oct; 47(5):413-6. PubMed ID: 17910106
[TBL] [Abstract][Full Text] [Related]
18. Effects of phenotype and genotype on methods for detection of extended-spectrum-beta-lactamase-producing clinical isolates of Escherichia coli and Klebsiella pneumoniae in Norway.
Tofteland S; Haldorsen B; Dahl KH; Simonsen GS; Steinbakk M; Walsh TR; Sundsfjord A;
J Clin Microbiol; 2007 Jan; 45(1):199-205. PubMed ID: 17079502
[TBL] [Abstract][Full Text] [Related]
19. In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae.
Aktaş Z; Kayacan C; Oncul O
Int J Antimicrob Agents; 2012 Jan; 39(1):86-9. PubMed ID: 22041508
[TBL] [Abstract][Full Text] [Related]
20. Strategies to overcome extended-spectrum β-lactamases (ESBLs) and AmpC β-lactamases in shigellae.
Livermore DM; Mushtaq S; Nguyen T; Warner M
Int J Antimicrob Agents; 2011 May; 37(5):405-9. PubMed ID: 21276715
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
